InsiderDirector

Clay B Siegall Insider Trading Activity

Every SEC Form 4 transaction reported by Clay B Siegall, sourced directly from SEC EDGAR and updated as new filings are accepted.

By · SEC Form 4 & insider trading data analysts
Last updated:

Quick Answer

Is Clay B Siegall buying or selling?

Clay B Siegall reported 10 open-market buys ($7.5M) and 57 sells ($166.6M) across 67 Form 4 filings at 4 companies — a net selling position of $159.1M.

Source: SEC EDGAR Form 4

Key Statistics (as of Jun 11, 2026)

Total Form 4 filings
67
SEC EDGAR
Companies
4
Buys (10)
$7.5M
Sells (57)
$166.6M

Insider sentiment

Net selling

Net insider flow of $159.1M in net selling, filed between May 12, 2018 – Jun 11, 2026.

Companies Clay B Siegall files for

#CompanyForm 4 filings
1SGENSEATTLE GENETICS INC /WA56
2IMNMImmunome Inc.9
3RAREUltragenyx Pharmaceutical Inc.1
4STTKShattuck Labs, Inc.1

Recent Clay B Siegall transactions

DateTickerRoleTypeSharesValue
Jun 11, 2026STTKDirectorPurchase62.5K$250.0K
Mar 31, 2026IMNMPresident and CEOPurchase25.4K$500.6K
Dec 30, 2025IMNMPresident and CEOPurchase4.7K$100.0K
Dec 22, 2025IMNMPresident and CEOPurchase7.3K$149.1K
Dec 18, 2025IMNMPresident and CEOPurchase46.5K$1000.0K
Mar 26, 2025IMNMPresident and CEOPurchase137.1K$999.5K
Feb 4, 2025IMNMPresident and CEOPurchase150.0K$1.2M
Nov 25, 2024IMNMPresident and CEOPurchase100.0K$962.2K
May 21, 2024IMNMPresident and CEOPurchase100.0K$1.4M
Oct 4, 2023IMNMPresident and CEOPurchase169.2K$1000.0K
May 13, 2022SGENPresident & CEOSale17.0K$2.1M
Apr 23, 2022SGENPresident & CEOSale1.9K$272.0K
Apr 9, 2022SGENPresident and CEOSale17.0K$2.6M
Mar 10, 2022SGENPresident & CEOSale17.0K$2.3M
Feb 10, 2022SGENPresident & CEOSale17.0K$2.4M
Jan 12, 2022SGENPresident & CEOSale17.0K$2.5M
Dec 22, 2021SGENPresident & CEOSale1.2K$183.9K
Dec 9, 2021SGENPresident & CEOSale45.4K$6.8M
Sep 2, 2021SGENPresident & CEOSale14.4K$2.4M
Sep 1, 2021SGENPresident and CEOSale60.4K$10.1M
Aug 19, 2021SGENPresident & CEOSale2.8K$431.1K
Aug 7, 2021SGENPresident & CEOSale29.4K$4.8M
Jul 7, 2021SGENPresident and CEOSale29.4K$4.6M
Jun 5, 2021SGENPresident and CEOSale29.4K$4.2M
May 7, 2021SGENPresident and CEOSale29.4K$4.0M

Showing the 25 most recent filings of 67. Screen every filing.

Clay B Siegall insider trading FAQ

Is Clay B Siegall buying or selling?

Across 67 SEC Form 4 filings, Clay B Siegall reported 10 open-market purchases totaling $7.5M and 57 sales totaling $166.6M — a net selling position of $159.1M.

Which companies does Clay B Siegall file Form 4s for?

Clay B Siegall has reported insider transactions at 4 companies, most often SEATTLE GENETICS INC /WA (SGEN), Immunome Inc. (IMNM), Ultragenyx Pharmaceutical Inc. (RARE), Shattuck Labs, Inc. (STTK).

How far back does Clay B Siegall's filing history go?

Trabud holds Clay B Siegall's SEC Form 4 filings from May 12, 2018 – Jun 11, 2026, sourced directly from SEC EDGAR.

Where does Trabud get Clay B Siegall's insider trading data?

Directly from SEC EDGAR Form 4 filings. Every transaction on this page is a real filing accepted by the SEC, updated as new filings arrive.

Related Content

Learn

What is SEC Form 4?

The filing behind every transaction here

Guide

How to Track Insider Trading

A practical workflow for following Form 4 activity

Use Case

Insider Buying Signals

How investors read insider purchases

Track Clay B Siegall and every other insider

Screen all SEC Form 4 filings by insider, company, transaction value, and role — or ask Trabud's AI agent in plain English.

Open the screener